Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα_q and Gα₁₁ and kill uveal melanoma cells

References

• PDQ Adult Treatment Editorial Board. Intraocular (Uveal) melanoma treatment (PDQ®): health professional version. PDQ cancer information summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–2018 Sep 20.
   Google Scholar
• Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, Pfeffer U. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36:109–140.
   PubMed Web of Science ®Google Scholar
• Tschentscher F, Hüsing J, Hölter T, Kruse E, Dresen IG, Jöckel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63:2578–2584.
   PubMed Web of Science ®Google Scholar
• Khan AQ, Kuttikrishnan S, Siveen KS, Prabhu KS, Shanmugakonar M, Al-Naemi HA, Haris M, Dermime S, Uddin S. RAS-mediated oncogenic signaling pathways in human malignancies. Semin Cancer Biol. 2018 Mar 7;S1044-579X(18)30002–6.
   Web of Science ®Google Scholar
• Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW. Driver Mutations in Uveal Melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134:728–733. doi:10.1001/jamaophthalmol.2016.0903.
   PubMed Web of Science ®Google Scholar
• O’Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014;27:126–135. doi:10.1016/j.ceb.2014.01.005.
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599–602. doi:10.1038/nature07586.
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191–2199. doi:10.1056/NEJMoa1011205.
   PubMed Web of Science ®Google Scholar
• Koopmans AE, Vaarwater J, Paridaens D, Naus NC, Kilic E, de Klein A. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer. 2013;109:493–496. doi:10.1038/bjc.2013.299.
   PubMed Web of Science ®Google Scholar
• Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:5230–5234. doi:10.1167/iovs.07-0624.
   PubMed Web of Science ®Google Scholar
• Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205–7209. doi:10.1158/0008-5472.CAN-04-1750.
   PubMed Web of Science ®Google Scholar
• Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, Haydu LE, Asher M, Zimmer L, Hillen U, et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol. 2014;27:175–183. doi:10.1038/modpathol.2013.138.
   PubMed Web of Science ®Google Scholar
• Giulietti M, Vivenzio V, Piva F1, Principato G, Bellantuono C, Nardi B. How much do we know about the coupling of G-proteins to serotonin receptors? Mol Brain. 2014;7:49. doi:10.1186/s13041-014-0049-y.
   PubMed Web of Science ®Google Scholar
• Ivey K, Tyson B, Ukidwe P, McFadden DG, Levi G, Olson EN, Srivastava D, Wilkie TM. Galphaq and Galpha11 proteins mediate endothelin-1 signaling in neural crest-derived pharyngeal arch mesenchyme. Dev Biol. 2003;255:230–237.
   PubMed Web of Science ®Google Scholar
• Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, Taylor BS, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics. 2016;48:675–680. doi:10.1038/ng.3549.
   PubMed Web of Science ®Google Scholar
• Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7:4624–4631. doi:10.18632/oncotarget.6614.
   PubMedGoogle Scholar
• Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7:4624–4631. doi:10.18632/oncotarget.6614.
   PubMedGoogle Scholar
• Lyon AM, Tesmer JJ. Structural insights into phospholipase C-beta function. Mol Pharmacol. 2013;84:488–500. doi:10.1124/mol.113.087403.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. Oncotarget. 2017;8:90262–90277. doi:10.18632/oncotarget.21660.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1/ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2018;19:132–137. doi:10.1080/15384047.2017.1394556.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. Oncotarget. 2017;9:6062–6074. doi:10.18632/oncotarget.23681.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Poklepovic A, Dent P. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition. Cancer Biol Ther. 2018 Sep;5:1–12. doi:10.1080/15384047.2018.1507665.
   Google Scholar
• Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P. Neratinib augments the lethality of [regorafenib + sildenafil]. J Cell Physiol. 2018 Sep 10. doi:10.1002/jcp.27276.
   Web of Science ®Google Scholar
• Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, et al. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Mol Pharmacol. 2007;71:259–275. doi:10.1124/mol.106.031153.
   PubMed Web of Science ®Google Scholar
• George AJ, Hannan RD, Thomas WG. Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches. FEBS J. 2013;280:5258–5268. doi:10.1111/febs.12509.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. 2016;7:19620–19630. doi:10.18632/oncotarget.7746.
   PubMed Web of Science ®Google Scholar
• Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Sci Signal. 2017;10:eaao3332. doi:10.1126/scisignal.aao3332.
   PubMed Web of Science ®Google Scholar
• Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, et al. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol. 2018;20:811–822. doi:10.1038/s41556-018-0122-3.
   PubMed Web of Science ®Google Scholar
• Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Australian Ovarian Cancer Study Group, Campbell IG, Gorringe KL. Genome Med. 2015;7:87. doi:10.1186/s13073-015-0210-y.
   PubMed Web of Science ®Google Scholar
• Cohen P, Hardie DG. The actions of cyclic AMP on biosynthetic processes are mediated indirectly by cyclic AMP-dependent protein kinase. Biochim Biophys Acta. 1991;1094:292–299.
   PubMed Web of Science ®Google Scholar
• Cohen P. Dissection of the protein phosphorylation cascades involved in insulin and growth factor action. Biochem Soc Trans. 1993;21:555–567.
   PubMed Web of Science ®Google Scholar
• Omar B, Zmuda-Trzebiatowska E, Manganiello V, Göransson O. Degerman E Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal. 2009;21:760–766. doi:10.1016/j.cellsig.2009.01.015.
   PubMed Web of Science ®Google Scholar
• Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17:528–542. doi:10.1038/nrc.2017.53.
   PubMed Web of Science ®Google Scholar
• Vaque JP, Dorsam RT, Feng X, Iglesias-Bartolome R, Forsthoefel DJ, Chen Q, Debant A., Seeger M.A., Ksander B.R., Teramoto H, et al. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. Mol Cell. 2013;49:94–108. doi:10.1016/j.molcel.2012.10.018.
   PubMed Web of Science ®Google Scholar
• Yonekawa T, Gamez G, Kim J, Tan AC, Thorburn J, Gump J, Thorburn A, Morgan MJ. RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis. EMBO Rep. 2015;16:700–708. doi:10.15252/embr.201439496.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017;8:16367–16386. doi:10.18632/oncotarget.14829.
   PubMedGoogle Scholar
• Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, Walker CL, Wogan GN. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proc Natl Acad Sci U S A. 2013;110:E2950–7. doi:10.1073/pnas.1307736110.
   PubMed Web of Science ®Google Scholar
• Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell. 2001;12:2629–2645. doi:10.1091/mbc.12.9.2629.
   PubMed Web of Science ®Google Scholar
• Delos Santos RC, Garay C, Antonescu CN. Charming neighborhoods on the cell surface: plasma membrane microdomains regulate receptor tyrosine kinase signaling. Cell Signal. 2015;27:1963–1976. doi:10.1016/j.cellsig.2015.07.004.
   PubMed Web of Science ®Google Scholar
• Jensen DE1, Rauscher FJ 3rd. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci. 1999;886:191–194.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, et al. Selumetinib in combination with Dacarbazine in patients with Metastatic Uveal Melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36:1232–1239. doi:10.1200/JCO.2017.74.1090.
   PubMed Web of Science ®Google Scholar
• Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, Coupland SE, Roose JP, Bastian BC. RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma. Cancer Cell. 2017;31:685–696. doi:10.1016/j.ccell.2017.04.002.
   PubMed Web of Science ®Google Scholar
• Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. Co-targeting HGF/cMET signaling with MEK inhibitors in metastatic uveal melanoma. Mol Cancer Ther. 2017;16:516–528. doi:10.1158/1535-7163.MCT-16-0552.
   PubMed Web of Science ®Google Scholar
• Kirchberger MC, Moreira A, Erdmann M, Schuler G, Heinzerling L. Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. Oncotarget. 2018;9:28903–28909. doi:10.18632/oncotarget.25627.
   PubMedGoogle Scholar
• Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, et al. Afatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med. 2018;10:eaao2301. doi:10.1126/scitranslmed.aao4496.
   PubMed Web of Science ®Google Scholar
• Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, Clark W, Hedley A, Laing S, Coffelt SB, et al. The ERBB network facilitates KRAS-driven lung tumorigenesis. Sci Transl Med. 2018;10:eaao2565. doi:10.1126/scitranslmed.aao4496.
   PubMed Web of Science ®Google Scholar